| Recruiting | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metast NCT04119024 | Anusha Kalbasi | Phase 1 |
| Recruiting | Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Met NCT05588453 | Kari Kendra | Phase 1 / Phase 2 |
| Active Not Recruiting | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Bra NCT05341349 | Emory University | Phase 1 |
| Recruiting | Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases NCT05026983 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or NCT04940299 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | 7T MRI Scan for the Early Detection of Melanoma Brain Metastases NCT04941430 | University of Southern California | N/A |
| Terminated | Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma NCT04527549 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Terminated | Bone Loss in Melanoma Survivors Receiving Immunotherapy NCT04516122 | M.D. Anderson Cancer Center | — |
| Terminated | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progress NCT04902040 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer NCT03819296 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases NCT04752267 | University of Southern California | EARLY_Phase 1 |
| Active Not Recruiting | Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV NCT04462406 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Terminated | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases NCT04789668 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab i NCT04511013 | SWOG Cancer Research Network | Phase 2 |
| Terminated | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype NCT04375527 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With M NCT04645680 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma Patients NCT05102773 | Ohio State University Comprehensive Cancer Center | — |
| Active Not Recruiting | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or M NCT03816332 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma NCT03727789 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma NCT03865212 | Mayo Clinic | Phase 1 |
| Completed | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer NCT04067960 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain NCT03873818 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY NCT02650986 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Me NCT03175432 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Ipilimumab and Imatinib Mesylate in Advanced Cancer NCT01738139 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases NCT01644591 | M.D. Anderson Cancer Center | Phase 2 |